Latest news with #VitaminD3
Business Standard
17 hours ago
- Business
- Business Standard
Fermenta FY25 Revenues INR 481.3 cr, up 39% YoY; Net Profit INR 76.4 cr vs year-ago loss
PRNewswire Mumbai (Maharashtra) [India], May 29: Fermenta Biotech Limited, India's leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals for the global markets, today announced that its consolidated revenue (other than from real estate) for the financial year ended 31 March 2025 was INR 427.0 crore, up 57% from the same year-ago period; EBITDA for FY25 was INR 83.3 crore against loss of INR 22.3 crore a year Revenue for FY25 INR 481.3 crore, up by INR 134 crore YoY. Consolidated EBITDA for FY25 INR 121.6 crore, up 209% YoY. Q4FY25 Consolidated Revenues INR 143.7 crore, up 40% YoY; down 9% QoQ. Performance highlights * Human nutrition volume grew by 48% over FY24 * Animal nutrition volume grew by 24% over FY24 * The company successfully completed validation batches for its spray dried (SD) variant of Vitamin D3 100,000 IU/g powder for human nutrition - Vitamin D3 100 SD and started qualification process with leading global customers and regulatory authorities. * The company also successfully completed commercial scale production of its plant based Vitamin D3 active ingredient using its proprietary technology developed in-house and completed validation batches of its plant based D3 in Oil and D3 spray dried powder variants for human nutrition-Vitadee Green™ 1 MIU Oil and Vitadee Green™ 100 SD and started qualification process with leading global customers and regulatory authorities. * Fermenta received letter of approval from GAIN, reinforcing its global commitment to quality and nutrition * Our German subsidiary showed standalone FY25 revenue of INR 38.2 crore, 412% growth from INR 7.5 crore a year ago, with EBITDA of INR 13.9 crore, against loss of INR 9.2 crore a year ago. Our US subsidiary showed revenue of INR 50.4 crore, up 81% from INR 27.8 crore a year ago with EBITDA at INR 0.5 crore loss, against INR 1.6 crore loss a year ago Commenting on the results, Prashant Nagre, Managing Director, said: "FY25 marks Fermenta's complete operational turnaround, validating our strategic focus and unwavering commitment to excellence. Strong volume recovery in our core Vitamin D3 business, successful geographic expansion across Latin America and Southeast Asia, and breakthrough innovations like Vitadee Green™--the world's first pharmacopeial-grade plant-based Vitamin D3--demonstrate our resilience and technical leadership. With strong cash flows, improved margins across all product lines, and new value-added products gaining meaningful market traction, we've built a robust foundation for sustained growth. Our disciplined approach to capital allocation, proactive risk management, and strategic partnerships position us to capitalize on emerging opportunities while advancing our vision of top-quality global nutritional wellness for all." About Fermenta Biotech Limited Fermenta Biotech Limited delivers best in class, science-backed nutritional ingredients across a wide range of market segments, including Pharmaceuticals, Dietary Supplements, Food & Beverages, and Veterinary. State-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh) and Dahej (Gujarat) drive FBL's comprehensive portfolio of premium vitamins, nutritional premixes, and ingredients for Human and Animal Nutrition. Our products and services cater to the exacting standards of the world's leading pharma, dietary supplements and food brands, and veterinary and animal feed producers for best-in-class solutions that enhance health, support preventive care, and drive life productivity. With decades of expertise at global-scale complex manufacturing, we also provide research-based custom solutions in green chemistry and environmental solutions. Financial Statements can be accessed through this link: Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this release. Such information and opinions are in all events not current after the date of this release. Certain statements made in this release may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Fermenta Biotech Limited ("Company" or "FBL" or Fermenta), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this release are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This release is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This release does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. This release is confidential and may not be copied or disseminated, in whole or in part, and in any manner. For further details, please contact: For Fermenta Biotech Limited:
Business Upturn
17 hours ago
- Health
- Business Upturn
How Vitamin D3 deficiency affects your overall wellness and how to fix it
Vitamin D3 or cholecalciferol is a crucial nutrient that plays a pivotal role in maintaining your overall health. It is particularly renowned for its role in bone density, the immune system, and energy. Sadly, most of the world's population lacks this vital vitamin, particularly in areas where the environment receives minimal sun exposure. In this article, we will see how vitamin D3 deficiency impacts your well-being and what you can do, including taking vitamin D3 drops, to correct it naturally and effectively. What is Vitamin D3? Vitamin D3 drop is the bioactive form of vitamin D your body makes when your skin is exposed to sunlight. It assists in the intestinal absorption of calcium and phosphorus, so it's essential for bone formation. D3 is different from some of the other vitamins because it's more of a hormone that can affect everything from cell growth to immune system modulation. Causes of Vitamin D3 Deficiency Vitamin D3 deficiency develops when your body fails to manufacture sufficient D3 or you lack sufficient amounts in your diet or supplements. Several reasons may play a role in this: Less sun exposure Darker complexions (which lower D3 production) Wearing sunscreen Ageing (older individuals manufacture less D3) Obesity Certain medications or health problems that influence absorption Symptoms of Vitamin D3 Deficiency Vitamin D3 deficiency might not present with immediate symptoms, but it can impact various areas of your health over time. Some of the common signs are: Fatigue and low energy Muscle weakness and cramps Bone pain or frequent fractures Mood swings or depression Increased susceptibility to infections Hair thinning These signs are usually nonspecific and ignored, so regular check-ups or preventive supplementation are essential. How Vitamin D3 Deficiency Affects Your Wellness 1. Weak Bones and Teeth Vitamin D3 aids in the absorption of calcium into bones. Deficiency can cause osteopenia and osteoporosis, making bones brittle and more susceptible to fracture. In kids, it can lead to rickets, leading to bone deformities. 2. Reduced Immunity Vitamin D3 regulates the immune system, aiding your body to combat infections. Deficiency can lead to heightened risks of colds, flu, and even autoimmune diseases. 3. Impact on Mental Health Low vitamin D3 has been associated with mood disorders such as anxiety and depression. Vitamin D participates in serotonin formation, a neurotransmitter with an impact on mood. 4. Weak Muscles Lack of vitamin D3 leads to muscular pain and weakness, which are more noticeable among the older generation. The chances of injuries and falls go up. 5. Persistent Fatigue Fatigue is a frequent but not specific symptom. Research indicates that normalization of vitamin D3 will improve energy and alleviate fatigue. Diagnosing Vitamin D3 Deficiency Vitamin D3 deficiency is best diagnosed by a routine blood test known as 25-hydroxy vitamin D. A reading less than 20 ng/mL is considered deficient, and 20–30 ng/mL is less than optimal. The best range is generally 30–60 ng/mL, although this will slightly vary with lab and region. How to Improve Vitamin D3 Deficiency 1. Catch More Sun The sun itself is the ultimate natural source of vitamin D3. Being exposed to 15–20 minutes of sunlight, ideally between the hours of 10 am to 3 pm, at least three times weekly, should serve. But perhaps not for sun-worriers living in very cold climates, or those darker-skinned types. 2. Take Vitamin-D-Fortified Foods Introducing the below foods can ensure higher D3 levels: Fatty fish (salmon, sardines, mackerel) Egg yolks Fortified foods (milk, cereals, orange juice) Cheese Beef liver Although these foods help, dietary intake alone typically does not suffice to rectify deficiency. 3. Take Supplements Supplements are a safe and convenient method to replenish D3 levels. They exist in numerous forms, such as tablets, capsules, and vitamin D3 drops. Drops are particularly helpful for children, the elderly, and individuals with issues swallowing pills. Why Use Vitamin D3 Drops? Vitamin D3 drops are a convenient and effective way to get the correct dosage, particularly for: Infants and toddlers Pregnant and lactating women Individuals with malabsorption disorders Individuals who find liquids more convenient than pills These drops are often flavourless and can be incorporated into food or beverages, making them convenient. Vitamin D3 Dosage Guidelines Always obtain a prescription from a healthcare professional prior to commencing any supplement. General dosage recommendations are: Infants (0–12 months): 400 IU/day Children (1–18 years): Between 600–1000 IU/day Adults (19–70 years): Between 600–2000 IU/day Elderly (70+ years): Between 800–2000 IU/day Those with deficiency: Higher doses can be temporarily prescribed Can You Overdose on Vitamin D3? Yes, although it is rare, excessive consumption can lead to vitamin D toxicity, causing hypercalcemia (high calcium levels). The symptoms are: Nausea and vomiting Frequent urination Kidney issues Always follow prescribed doses and check levels if you are on long-term supplementation. Tips for Better Absorption Take vitamin D3 with a meal that includes healthy fats. Avoid high-fibre foods when taking supplements, as they can lower absorption. Take with magnesium-containing foods or supplements, which aid in the activation of D3. Conclusion Vitamin D3 is essential for a robust immune system, healthy bones, a balanced mood, and overall energy. Deficiency in vitamin D3 is common but also readily curable. You can restore the best levels and feel better again by more sunlight, diet, or supplements such as vitamin D3 drops. Don't ignore signs of deficiency at their onset. Do your own thing and make a visit to your doctor to assess your current levels and optimum method for improvement.
Business Upturn
19 hours ago
- Business
- Business Upturn
Fermenta FY25 Revenues INR 481.3 cr, up 39% YoY; Net Profit INR 76.4 cr vs year-ago loss
BSE: 506414 Bloomberg: FERMENTA:IN Reuters: Consolidated Revenue for FY25 INR 481.3 crore , up by INR 134 crore YoY , up by INR YoY Consolidated EBITDA for FY25 INR 121.6 crore , up 209% YoY , up 209% YoY Q4FY25 Consolidated Revenues INR 143.7 crore , up 40% YoY; down 9% QoQ MUMBAI, India , May 29, 2025 /PRNewswire/ — Fermenta Biotech Limited, India's leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals for the global markets, today announced that its consolidated revenue (other than from real estate) for the financial year ended 31 March 2025 was INR 427.0 crore , up 57% from the same year-ago period; EBITDA for FY25 was INR 83.3 crore against loss of INR 22.3 crore a year ago. Key financials (consolidated) without real estate Q4FY25 FY25 Revenue INR 133.8 crore (up 36% YoY, up 11% QoQ) INR 427.0 crore (up 57% YoY) EBITDA INR 32.2 crore (up 200% YoY, up 30% QoQ) INR 83.3 crore (up by INR 105.6 crore YoY) Key financials (consolidated) with real estate Q4FY25 FY25 Revenue INR 143.7 crore (up 40% YoY, down 9% QoQ) INR 481.3 crore (up 39% YoY) EBITDA INR 40.8 crore (up 280% YoY, down 26% QoQ) INR 121.6 crore (up 209% YoY) Profit after tax INR 33.3 crore (up INR 40.5 crore YoY, down 12% QoQ) INR 76.4 crore (up INR 100.4 crore YoY) EPS after exceptional item INR 11.79 INR 26.35 Performance highlights Human nutrition volume grew by 48% over FY24 Animal nutrition volume grew by 24% over FY24 The company successfully completed validation batches for its spray dried (SD) variant of Vitamin D3 100,000 IU/g powder for human nutrition – Vitamin D3 100 SD and started qualification process with leading global customers and regulatory authorities. The company also successfully completed commercial scale production of its plant based Vitamin D3 active ingredient using its proprietary technology developed in-house and completed validation batches of its plant based D3 in Oil and D3 spray dried powder variants for human nutrition-Vitadee Green™ 1 MIU Oil and Vitadee Green™ 100 SD and started qualification process with leading global customers and regulatory authorities. Fermenta received letter of approval from GAIN, reinforcing its global commitment to quality and nutrition Our German subsidiary showed standalone FY25 revenue of INR 38.2 crore , 412% growth from INR 7.5 crore a year ago, with EBITDA of INR 13.9 crore , against loss of INR 9.2 crore a year ago. Our US subsidiary showed revenue of INR 50.4 crore , up 81% from INR 27.8 crore a year ago with EBITDA at INR 0.5 crore loss, against INR 1.6 crore loss a year ago Commenting on the results, Prashant Nagre , Managing Director, said: 'FY25 marks Fermenta's complete operational turnaround, validating our strategic focus and unwavering commitment to excellence. Strong volume recovery in our core Vitamin D3 business, successful geographic expansion across Latin America and Southeast Asia , and breakthrough innovations like Vitadee Green™—the world's first pharmacopeial-grade plant-based Vitamin D3—demonstrate our resilience and technical leadership. With strong cash flows, improved margins across all product lines, and new value-added products gaining meaningful market traction, we've built a robust foundation for sustained growth. Our disciplined approach to capital allocation, proactive risk management, and strategic partnerships position us to capitalize on emerging opportunities while advancing our vision of top-quality global nutritional wellness for all.' Revenue mix (consolidated) FY25 (INR crore) FY24 (INR crore) YoY change (%) Nutrition Business Vitamin D3 – Human Nutrition 216.3 140.5 +54 % Vitamin D3 – Animal Nutrition 94.0 38.2 +146 % Others 40.0 38.7 +3 % Other Business Other APIs and Intermediates 37.5 28.6 +31 % Green Chemistry Solutions / Enzymes 7.0 5.4 +30 % Environmental Solutions 22.2 11.8 +88 % Other Income 19.6 20.4 -4 % Value Unlocking Real Estate 44.6 63.9 -30 % Geographical revenue mix (consolidated) excluding real estate value unlocking FY25 FY24 Change (%) India 40 % 46 % -6 % Europe 27 % 20 % +7 % North America 17 % 13 % +4 % Others 16 % 20 % -4 % About Fermenta Biotech Limited Fermenta Biotech Limited delivers best in class, science-backed nutritional ingredients across a wide range of market segments, including Pharmaceuticals, Dietary Supplements, Food & Beverages, and Veterinary. State-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh) and Dahej (Gujarat) drive FBL's comprehensive portfolio of premium vitamins, nutritional premixes, and ingredients for Human and Animal Nutrition. Our products and services cater to the exacting standards of the world's leading pharma, dietary supplements and food brands, and veterinary and animal feed producers for best-in-class solutions that enhance health, support preventive care, and drive life productivity. With decades of expertise at global-scale complex manufacturing, we also provide research-based custom solutions in green chemistry and environmental solutions. Financial Statements can be accessed through this link: Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this release. Such information and opinions are in all events not current after the date of this release. Certain statements made in this release may not be based on historical information or facts and may be 'forward looking statements' based on the currently held beliefs and assumptions of the management of Fermenta Biotech Limited ('Company' or 'FBL' or Fermenta), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this release are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This release is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This release does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. This release is confidential and may not be copied or disseminated, in whole or in part, and in any manner. For further details, please contact:For Fermenta Biotech Limited:Mr. Prashant Nagre Managing Director [email protected]
Yahoo
19 hours ago
- Business
- Yahoo
Fermenta FY25 Revenues INR 481.3 cr, up 39% YoY; Net Profit INR 76.4 cr vs year-ago loss
BSE: 506414 Bloomberg: FERMENTA:IN Reuters: Consolidated Revenue for FY25 INR 481.3 crore, up by INR 134 crore YoY Consolidated EBITDA for FY25 INR 121.6 crore, up 209% YoY Q4FY25 Consolidated Revenues INR 143.7 crore, up 40% YoY; down 9% QoQ MUMBAI, India, May 29, 2025 /PRNewswire/ -- Fermenta Biotech Limited, India's leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals for the global markets, today announced that its consolidated revenue (other than from real estate) for the financial year ended 31 March 2025 was INR 427.0 crore, up 57% from the same year-ago period; EBITDA for FY25 was INR 83.3 crore against loss of INR 22.3 crore a year ago. Key financials (consolidated) without real estateQ4FY25 FY25 Revenue INR 133.8 crore (up 36% YoY, up 11% QoQ) INR 427.0 crore (up 57% YoY) EBITDA INR 32.2 crore (up 200% YoY, up 30% QoQ) INR 83.3 crore (up by INR 105.6 crore YoY) Key financials (consolidated) with real estateQ4FY25 FY25 Revenue INR 143.7 crore (up 40% YoY, down 9% QoQ) INR 481.3 crore (up 39% YoY) EBITDA INR 40.8 crore (up 280% YoY, down 26% QoQ) INR 121.6 crore (up 209% YoY) Profit after tax INR 33.3 crore (up INR 40.5 crore YoY, down 12% QoQ) INR 76.4 crore (up INR 100.4 crore YoY) EPS after exceptional item INR 11.79 INR 26.35 Performance highlights Human nutrition volume grew by 48% over FY24 Animal nutrition volume grew by 24% over FY24 The company successfully completed validation batches for its spray dried (SD) variant of Vitamin D3 100,000 IU/g powder for human nutrition - Vitamin D3 100 SD and started qualification process with leading global customers and regulatory authorities. The company also successfully completed commercial scale production of its plant based Vitamin D3 active ingredient using its proprietary technology developed in-house and completed validation batches of its plant based D3 in Oil and D3 spray dried powder variants for human nutrition-Vitadee Green™ 1 MIU Oil and Vitadee Green™ 100 SD and started qualification process with leading global customers and regulatory authorities. Fermenta received letter of approval from GAIN, reinforcing its global commitment to quality and nutrition Our German subsidiary showed standalone FY25 revenue of INR 38.2 crore, 412% growth from INR 7.5 crore a year ago, with EBITDA of INR 13.9 crore, against loss of INR 9.2 crore a year ago. Our US subsidiary showed revenue of INR 50.4 crore, up 81% from INR 27.8 crore a year ago with EBITDA at INR 0.5 crore loss, against INR 1.6 crore loss a year ago Commenting on the results, Prashant Nagre, Managing Director, said: "FY25 marks Fermenta's complete operational turnaround, validating our strategic focus and unwavering commitment to excellence. Strong volume recovery in our core Vitamin D3 business, successful geographic expansion across Latin America and Southeast Asia, and breakthrough innovations like Vitadee Green™—the world's first pharmacopeial-grade plant-based Vitamin D3—demonstrate our resilience and technical leadership. With strong cash flows, improved margins across all product lines, and new value-added products gaining meaningful market traction, we've built a robust foundation for sustained growth. Our disciplined approach to capital allocation, proactive risk management, and strategic partnerships position us to capitalize on emerging opportunities while advancing our vision of top-quality global nutritional wellness for all." Revenue mix (consolidated)FY25 (INR crore) FY24 (INR crore) YoY change (%) Nutrition Business Vitamin D3 – Human Nutrition 216.3 140.5 +54 % Vitamin D3 – Animal Nutrition 94.0 38.2 +146 % Others 40.0 38.7 +3 % Other Business Other APIs and Intermediates 37.5 28.6 +31 % Green Chemistry Solutions / Enzymes 7.0 5.4 +30 % Environmental Solutions 22.2 11.8 +88 % Other Income 19.6 20.4 -4 % Value Unlocking Real Estate 44.6 63.9 -30 % Geographical revenue mix (consolidated) excluding real estate value unlockingFY25 FY24 Change (%) India 40 % 46 % -6 % Europe 27 % 20 % +7 % North America 17 % 13 % +4 % Others 16 % 20 % -4 % About Fermenta Biotech Limited Fermenta Biotech Limited delivers best in class, science-backed nutritional ingredients across a wide range of market segments, including Pharmaceuticals, Dietary Supplements, Food & Beverages, and Veterinary. State-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh) and Dahej (Gujarat) drive FBL's comprehensive portfolio of premium vitamins, nutritional premixes, and ingredients for Human and Animal Nutrition. Our products and services cater to the exacting standards of the world's leading pharma, dietary supplements and food brands, and veterinary and animal feed producers for best-in-class solutions that enhance health, support preventive care, and drive life productivity. With decades of expertise at global-scale complex manufacturing, we also provide research-based custom solutions in green chemistry and environmental solutions. Financial Statements can be accessed through this link: Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this release. Such information and opinions are in all events not current after the date of this release. Certain statements made in this release may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Fermenta Biotech Limited ("Company" or "FBL" or Fermenta), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this release are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This release is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This release does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. This release is confidential and may not be copied or disseminated, in whole or in part, and in any manner. For further details, please contact:For Fermenta Biotech Limited:Mr. Prashant Nagre Managing Director Logo: View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
India Today
2 days ago
- Health
- India Today
Fuel Your Body with These Top Vitamin D-Rich Foods
Fuel Your Body with These Top Vitamin D-Rich Foods BY: Kashmik Singh Chouhan Your best free source of Vitamin D is early morning sunlight. Expose your face, arms, and legs for 15–20 minutes daily without sunscreen. It triggers Vitamin D synthesis through the skin and supports mood, immunity, and bone strength. Sunlight (Natural Synthesis) Fatty fish like salmon, mackerel, and tuna are rich in Vitamin D3 and omega-3s. A 100g serving of salmon can provide over 50% of your daily Vitamin D needs. Grill, bake, or toss into salads for a nutritious boost. Fatty Fish Egg yolks are one of the easiest whole-food sources of Vitamin D. One large yolk provides around 5%–10% of your daily requirement. Include boiled or sunny-side-up eggs in breakfast for a nutrient-packed start. Egg Yolks Cow's milk and fortified plant-based milks (like soy, almond, and oat milk) often have added Vitamin D2 or D3. Check the label and choose unsweetened options. Perfect for smoothies, cereals, or coffee. Fortified Milk & Plant-Based Alternatives Some spreads and butters are fortified with Vitamin D to aid absorption of calcium. Use them in moderation on whole grain toast or in cooking to sneak in daily requirements. Fortified Butter & Margarine Certain types of processed cheese and paneer are now fortified with Vitamin D, especially in India. Check for brands with added nutrients. Add them to parathas, salads, or toast. Fortified Cheese & Paneer Mushrooms like maitake and UV-exposed button mushrooms are the only vegan natural source of Vitamin D. They synthesize D2 when exposed to sunlight. Add to stir-fries, soups, or sautés. Mushrooms (Exposed to UV Light) Many ready-to-eat cereals are fortified with Vitamin D, especially those aimed at kids and women. Choose whole grain, low-sugar options and pair with fortified milk for a double boost. Fortified Breakfast Cereals A traditional yet powerful source, cod liver oil provides a mega dose of Vitamin D and A. One teaspoon meets nearly 100% of daily Vitamin D needs. Best taken under guidance, especially for kids or pregnant women. Cod Liver Oil (Supplemental) If you're low on sun exposure or have medical deficiencies, supplements (D2 or D3) are effective. Always consult a doctor for dosage. Best taken with meals for better absorption. Vitamin D Supplements (When Deficient)
